Key Takeaways
- • Jeito Capital closed its second fund, Jeito II, at €1bn ($1.2bn), establishing the largest raise ever by a fully independent European biopharma private equity fund and tripling the firm's total assets under management to €1.6bn.
- • The fund will deploy capital across 15–20 clinical-stage biopharma companies with average investment sizes of approximately €150m per company, up from its first fund, enabling accelerated clinical development and market access.
- • Jeito's track record demonstrates strong exit performance, with previous investments in EyeBio and Hi-Bio achieving acquisitions by Merck & Co and Biogen respectively, generating combined upfront payments of nearly $2.5bn with average holding periods of 24 months.
- • The fund attracted institutional-grade capital from sovereign and public funds, pharmaceutical companies, insurance groups, pension funds, family offices, and banks across Europe, North America, and Asia, reflecting confidence in the firm's biopharma investment thesis.
- • Jeito's investment strategy targets therapeutic areas with severe unmet medical needs, including oncology, autoimmune diseases, neurology, cardio-metabolic conditions, obesity, and reproductive medicine, supported by a 30-person multidisciplinary team providing operational and regulatory guidance.
Summary
Jeito Capital, an independent European private equity specialist focused on biopharma investments, has achieved final close on its second fund at €1bn ($1.2bn), representing a historic milestone as the largest capital raise by a fully independent European biopharma-focused fund. The closing triples Jeito's assets under management to €1.6bn and nearly doubles the capital deployed in its inaugural fund, signaling strong institutional demand for specialized biopharma investment expertise in Europe.
The fund will maintain Jeito's selective approach of backing 15–20 clinical-stage biopharma companies addressing severe diseases with high unmet medical needs. A key differentiator in Jeito II is the increased average investment per portfolio company, rising to approximately €150m, which positions the firm to provide deeper capital support for companies navigating critical clinical development phases and commercial scaling. This capital structure reflects a maturing thesis: larger cheques enable portfolio companies to reach critical regulatory milestones and market entry with reduced dilution and greater operational runway.
Jeito's investment track record provides empirical support for its strategy. Previous portfolio investments in EyeBio and Hi-Bio generated successful acquisitions by Merck & Co and Biogen, respectively, with combined upfront payments totaling nearly $2.5bn and average holding periods of 24 months. This performance demonstrates the firm's ability to identify clinical-stage assets, accelerate development timelines through operational support, and execute strategic exits with institutional acquirers—a compelling value proposition for limited partners.
The fund's investor base reflects broad institutional confidence in Jeito's approach. Capital came from sovereign and public funds, pharmaceutical companies, insurance groups, pension funds, family offices, and banks spanning Europe, North America, and Asia. This geographic and investor-type diversity suggests that Jeito II resonated with both traditional institutional allocators and strategic pharmaceutical investors seeking exposure to early-stage innovation.
Jeito's operational model underpins its investment thesis. The firm deploys a 30-person multidisciplinary team spanning drug development, regulatory affairs, intellectual property, commercial operations, and market access, providing portfolio companies with strategic guidance alongside capital. This embedded operational support addresses a critical gap in biopharma investing: many clinical-stage companies require not just capital but experienced expertise to navigate regulatory pathways, design efficient trials, and prepare for market entry. Jeito II's larger check sizes enable more intensive engagement with portfolio companies across these domains.
The fund will maintain Jeito's selective approach of backing 15–20 clinical-stage biopharma companies addressing severe diseases with high unmet medical needs. A key differentiator in Jeito II is the increased average investment per portfolio company, rising to approximately €150m, which positions the firm to provide deeper capital support for companies navigating critical clinical development phases and commercial scaling. This capital structure reflects a maturing thesis: larger cheques enable portfolio companies to reach critical regulatory milestones and market entry with reduced dilution and greater operational runway.
Jeito's investment track record provides empirical support for its strategy. Previous portfolio investments in EyeBio and Hi-Bio generated successful acquisitions by Merck & Co and Biogen, respectively, with combined upfront payments totaling nearly $2.5bn and average holding periods of 24 months. This performance demonstrates the firm's ability to identify clinical-stage assets, accelerate development timelines through operational support, and execute strategic exits with institutional acquirers—a compelling value proposition for limited partners.
The fund's investor base reflects broad institutional confidence in Jeito's approach. Capital came from sovereign and public funds, pharmaceutical companies, insurance groups, pension funds, family offices, and banks spanning Europe, North America, and Asia. This geographic and investor-type diversity suggests that Jeito II resonated with both traditional institutional allocators and strategic pharmaceutical investors seeking exposure to early-stage innovation.
Jeito's operational model underpins its investment thesis. The firm deploys a 30-person multidisciplinary team spanning drug development, regulatory affairs, intellectual property, commercial operations, and market access, providing portfolio companies with strategic guidance alongside capital. This embedded operational support addresses a critical gap in biopharma investing: many clinical-stage companies require not just capital but experienced expertise to navigate regulatory pathways, design efficient trials, and prepare for market entry. Jeito II's larger check sizes enable more intensive engagement with portfolio companies across these domains.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.